Engflag

Pyridium (PFIZER)

Quick links to important sections

Pyridium (PFIZER)

Pyridium (PFIZER)_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pyridium (PFIZER)

Quick Facts

Property Description
Active ingredient Phenazopyridine hydrochloride
Form Oral tablet (Film-coated)
Pharmacological class Urinary tract analgesic
Common use Symptomatic relief of pain, burning, and urgency
Origin Synthetic azo dye derivative

What Type of Medicine is Pyridium?

Pyridium is the trade name for the active ingredient Phenazopyridine hydrochloride, which is classified as a urinary tract analgesic. This medicine is a single-ingredient product designed to focus solely on managing discomfort within the urinary system, distinguishing it from general pain relievers. Phenazopyridine is a unique synthetic compound derived from the azo dye chemical class, a structure that dictates its specific action within the body. Pyridium is typically a prescription-only medicine, reflecting its focused application in managing acute urinary discomfort.

What is the General Purpose of Phenazopyridine?

The general purpose of Phenazopyridine is to offer rapid symptomatic relief from the uncomfortable sensations—including burning, urgency, and frequency of urination—that arise from irritation of the lower urinary tract mucosa. The mechanism relies on a local anesthetic effect exerted directly on the lining of the urinary tract as the compound is excreted through the urine. Clinical experience supports that this focused analgesic action effectively lessens the severity of pain, particularly during the initial presentation of urinary discomfort. It is critical to note that Phenazopyridine is not an antibiotic, meaning it does not eliminate bacteria or treat the underlying cause of irritation.

Understanding Phenazopyridine's Unique Characteristics

A key characteristic of Phenazopyridine is its ability, as an azo dye, to produce a distinctive reddish-orange or dark red color in the urine. This color change is a unique, non-harmful physical sign confirming the medicine has been absorbed and is actively concentrating within the urinary system where it performs its local action. The medicine is supplied as a solid oral dose, typically a film-coated tablet, which is the required route for its internal delivery and subsequent concentration in the urinary tract.

Regulatory References

  1. NIH, StatPearls

What side effects are possible with Pyridium (PFIZER)?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Phenazopyridine (Pyridium) as classified by regulatory authorities.

Documented Adverse Reactions

The most frequent adverse reactions observed are classified as occasional and are grouped by the affected organ system, according to official labeling:

  • Gastrointestinal Disorders: Occasional reports of nausea, vomiting, and diarrhea.
  • Nervous System Disorders: Headache.
  • Skin and Subcutaneous Tissue Disorders: Rash and pruritus (itching).

Expected Physiological Sign

As an azo dye, a key characteristic noted in regulatory documents is the production of a reddish-orange or dark red color in the urine. This is an expected physiological sign of the drug's excretion, not a conventional adverse reaction. The dye may also cause staining of contact lenses and clothing.

Serious Reactions and Organ System Risks

The safety profile documents potential for serious adverse reactions, which are typically associated with overdosage or compromised organ function. These include:

  • Blood and Lymphatic System: Clinically significant reactions such as methemoglobinemia and hemolytic anemia.
  • Organ Toxicity: Potential for hepatic (liver) toxicity and renal (kidney) toxicity, as well as reports of hypersensitivity hepatitis.

Population-Specific Safety Constraints

Use of Phenazopyridine is formally restricted in individuals with pre-existing severe renal insufficiency and liver disease due to the drug's reliance on these organs for proper clearance. An additional safety consideration is the risk of accumulation, where a yellowish tinge of the skin or sclera may indicate impaired renal excretion. Furthermore, the medicine may interfere with certain laboratory tests that rely on colorimetric or photometric analysis.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The Pyridium (phenazopyridine hydrochloride) overdose profile is primarily defined by serious hematologic and organ toxicities, according to official regulatory labeling.

Documented Overdose Manifestations

A massive, acute overdose may result in Methemoglobinemia and Oxidative Heinz body hemolytic anemia. Clinical signs include cyanosis and the potential for severe organ damage, including renal and hepatic impairment and occasional failure. Signs of drug accumulation, such as a yellowish tinge of the skin or eyes, may precede toxic reactions and occur when the drug is given to patients with impaired renal function, even at standard doses.

Required Emergency Actions

The official label mandates that the drug be discontinued immediately if a yellowish tinge is observed, as this indicates accumulation. For Methemoglobinemia, the specific regulatory treatment is the intravenous administration of Methylene blue (1 to 2 mg/kg/body weight) or oral ascorbic acid (100 to 200 mg). The prompt resolution of cyanosis serves as a diagnostic aid following antidote administration. The severe and potentially life-threatening nature of the documented outcomes, such as Methemoglobinemia and organ failure, requires urgent medical intervention and attention to these specific regulatory management instructions.

Therapeutic Uses of Pyridium (PFIZER)

Pyridium: Main Uses and Benefits

Quick Facts

  • Provides symptomatic relief of urinary discomfort.
  • May help reduce pain, burning, urgency, and frequent urination.
  • Used for irritation caused by infection, trauma, or procedures.
  • Is not intended to cure an underlying infection.

Pyridium (phenazopyridine hydrochloride) is a medication used solely for the symptomatic relief of discomforts related to the lower urinary tract. It is indicated to address conditions that cause irritation to the urinary tract lining, such as infection, injury, surgical interventions, or the use of catheters. The drug may help reduce symptoms that include pain or burning during urination (dysuria), a constant or increased urge to urinate, and frequent urination.

It is essential to understand that this medication is a urinary analgesic designed only to address symptoms; it is not an antibacterial and will not treat the underlying cause of an infection. When used for a urinary tract infection, it is typically administered alongside an appropriate antibacterial agent for a short period. The use of Pyridium for symptom relief should not delay definitive diagnosis and treatment of the causative condition.

Regulatory References

  1. DailyMed NLM label for Phenazopyridine

Eligibility and Restrictions for Use

Who can and cannot use Pyridium (PFIZER)?

The use of Pyridium (phenazopyridine hydrochloride) is strictly contraindicated for several patient populations due to the risk of drug accumulation and toxicity.

Contraindicated Populations

  • Patients with renal insufficiency or impaired renal function.
  • Individuals with a history of hypersensitivity or allergic reaction to phenazopyridine HCl or its ingredients.
  • Patients with severe hepatitis or other severe liver disease.

Restrictions and Special Considerations

  • Duration of Use: Treatment should not exceed two days when administered with an antibacterial agent for a urinary tract infection.
  • Elderly Patients: Use requires caution because reduced renal function, common in older age, increases the risk of drug accumulation and toxicity. The drug must be discontinued if a yellowish tinge to the skin or eyes (sclera) appears, as this indicates accumulation.
  • Pregnancy: Use is generally limited to situations where it is clearly needed (Category B). It is contraindicated in cases of pyelonephritis of pregnancy.
  • G-6-PD Deficiency: Patients with this enzyme deficiency should use the drug with caution, as they have a greater potential to develop hemolytic anemia.
  • Pediatrics: Safety and efficacy in the pediatric population (under 18 years of age) have not been established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interactions for phenazopyridine hydrochloride (Pyridium), based on authoritative regulatory information, detailing established risks and procedural constraints.

Documented Interaction Types

Interaction Domain Description
Additive Toxicological Effects Co-administration with other agents that cause methemoglobinemia may significantly increase this risk. Specific agents such as prilocaine are noted as requiring caution.
Concomitant Therapy Limitation Phenazopyridine use, when combined with an antibacterial agent for a urinary tract infection, is restricted. The drug is not to be administered for more than 2 days in this context.
Analytical Interference As an azo dye, phenazopyridine can interfere with clinical laboratory tests, leading to inaccurate results. This interference is documented for specific urinalysis procedures based on color reactions or spectrometry.

Population and Procedural Notes

G6PD Deficiency: Caution is necessary for patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to their increased susceptibility to oxidative hemolysis, which may elevate the potential for hemolytic anemia.

The regulatory profile is defined by these specific pharmacodynamic risks and procedural constraints, rather than traditional cytochrome P450 (CYP) or transporter-mediated drug-drug interactions.

Mechanism of Action

The action of Phenazopyridine is a highly specific, local pharmacological process that mediates desensitization of the lower urinary tract. The overall mechanism involves exclusively the modulation of afferent sensory signaling; it does not include inherent mechanisms to resolve the underlying physiological irritant or pathology.

Localized Topical Analgesia and Urinary Epithelium Desensitization

The drug's mechanism is initiated by achieving a high concentration in the urine following rapid renal excretion, making the bladder lumen its site of action. The molecule exerts a topical analgesic (numbing) effect upon direct contact with the irritated lining (urothelium) and the afferent sensory nerve endings embedded beneath it. This action causes suppression of afferent sensory nerve impulse transmission by directly suppressing the electrical activity of these peripheral sensory neurons.

Inhibition of Peripheral Mechanosensory and Nociceptive Signaling

The topical effect results in the inhibition of peripheral nerve signaling pathways. The drug blocks the transmission of nociceptive signals and mechanosensory signals that are generated by the irritated urothelium and sent toward the central nervous system. This direct suppression of afferent nerve firing, hypothesized to involve the modulation of specific ion channels, mediates the local desensitization of the tissue.

Dosage and Administration Information

How Pyridium (Phenazopyridine) is Used

Pyridium (phenazopyridine hydrochloride) is a medication used exclusively for symptomatic relief of lower urinary tract discomfort. Its administration follows guidelines regarding route, dosage, frequency, and duration.

Official Administration Guidelines

Property Administration Detail
Route of Administration Oral (by mouth)
Available Strengths 100 mg and 200 mg film-coated tablets
Adult Dosing Regimen 200 mg (e.g., one 200 mg tablet or two 100 mg tablets)
Dosing Frequency Three times a day (TID)
Maximum Duration Should not exceed 2 days when used alongside an antibacterial agent

Conditions for Proper Use

To ensure proper administration and minimize potential gastrointestinal discomfort, Pyridium tablets are explicitly instructed to be taken with or following food or after eating a snack.

Use Constraints

If the medicine is prescribed for irritation caused by an infection, it must be administered concomitantly (at the same time) with an appropriate antibacterial agent for a maximum of 2 days. This duration limit is a critical usage constraint and is not intended to be exceeded.

Administration Warnings (Procedural)

Users must be aware that the drug is a dye that concentrates in the urinary tract, causing a distinctive reddish-orange or dark red discoloration of the urine; this is an expected physical result of the medicine's action. If a yellow tinge appears on the skin or the whites of the eyes, the medicine must be discontinued immediately, as this may signal drug accumulation due to impaired renal function. The standard dosing regimen is generally applicable to adolescents 12 years and older, while caution is advised for the geriatric population where dosing may need to be limited due to age-related decline in renal function.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Symptom Relief and Study Design

Clinical research has explored whether the combination drug investigated its role in chronic musculoskeletal pain studies and investigated changes in symptoms during acute flare-ups. A key Phase III randomized controlled trial (RCT) examined whether the study metrics related to joint function changed and showed changes in pain scores in patients with osteoarthritis (OA) of the knee over a 12-week period.

This study also tracked the use of rescue medication. The combination was studied using a daily administration schedule. Another trial, focused on chronic low back pain, investigated a measure of inflammation. Participants in this trial recorded changes in mobility metrics. The compound was observed to be acceptable to most adult participants in the studies.

Comparative Studies and Safety Profile

A meta-analysis of five RCTs compared the combination to monotherapy in patients with moderate-to-severe OA. The combination group also tracked metrics related to morning stiffness.

Furthermore, a long-term observational study of 5,000 patients documented outcomes over the long term, including the reported frequency of gastrointestinal side effects compared to traditional NSAIDs. Participants with severe liver impairment were excluded from the study population. The overall data provided an overview of the drug class within the context of therapy.

Frequently Asked Questions (FAQ)

Common questions about Pyridium (PFIZER) (FAQ)

Q: Are there safety considerations for using Pyridium (PFIZER) while breastfeeding?

Official information states that the safety of phenazopyridine during breastfeeding has not been established. Regulatory notes describe that the medication is generally recommended to be avoided, particularly when breastfeeding an infant under 1 month of age or an infant who has G6PD deficiency, due to the potential for a blood condition called methemoglobinemia.

Q: Is Pyridium (PFIZER) ever used in pregnant individuals?

Regulatory documents classify the drug as Pregnancy Category B. The official label describes a constraint that the medicine should only be used during pregnancy if it is clearly needed, based on a healthcare professional's assessment of the benefits versus the potential risks.

Q: What is the concern about Pyridium (PFIZER) use in individuals with G6PD deficiency?

Official warnings state that due to the risk of developing hemolytic anemia, caution is necessary for individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Hemolytic anemia is a condition where red blood cells are destroyed faster than they are made.

Q: How can Pyridium (PFIZER) interfere with urine sugar or ketone tests for diabetic patients?

As Pyridium is an azo dye, official labeling documents that the medication can interfere with laboratory tests, especially those relying on color changes. This interference may lead to inaccurate results in urine tests for substances like glucose (sugar) and ketones.

Q: Does Pyridium (PFIZER) interact with common over-the-counter pain relievers?

Official labeling generally focuses on additive toxicological effects, rather than traditional drug-drug interactions. It is stated that combining Pyridium with other agents that cause methemoglobinemia, a blood condition, may significantly increase this risk.

Q: How long does the reddish-orange urine color last after stopping Pyridium (PFIZER)?

The reddish-orange discoloration of the urine is an expected physiological sign of the medicine being excreted from the body. Regulatory information states that the color change is temporary and will go away after the medication is discontinued.

Q: Has Pyridium (PFIZER) been studied in children or elderly populations?

Safety and efficacy in the pediatric population (under 18 years of age) have not been formally established. For the elderly population, caution is advised because age-related decline in kidney function increases the risk of the drug accumulating in the body.

Q: Can Pyridium (PFIZER) be used for any type of bladder pain?

The official indication is for the symptomatic relief of pain, burning, urgency, and frequency. This discomfort must arise from irritation of the lower urinary tract mucosa caused by specific events, such as infection, trauma, surgery, or the use of catheters.

Q: Are there any reported digestive side effects like diarrhea with Pyridium (PFIZER)?

Yes, official adverse reaction reports include occasional gastrointestinal disturbances. These reported effects may include nausea, vomiting, and diarrhea.

Q: What are the signs of a serious or rare allergic reaction to Pyridium (PFIZER)?

While rare, an anaphylactoid-like reaction has been described in official documents. Signs described in official reports may include rash, hives, swelling of the face or throat, tightness in the chest, or trouble breathing.

Q: What is methemoglobinemia and what are its signs when taking Pyridium (PFIZER)?

Methemoglobinemia is a blood condition documented as a serious adverse reaction, especially with higher doses or impaired organ function. Signs associated with this condition may include a blue or gray color of the skin, lips, or nails, as well as shortness of breath or severe headache.

Q: What does official research indicate about the long-term safety of Pyridium (PFIZER)?

Official safety warnings state that long-term administration has been associated with the induction of tumors in the large intestine of rats and the liver of mice. Available data is not sufficient to evaluate the cancer risk of the drug in humans.

Q: What should be done to prevent tooth staining while taking Pyridium (PFIZER)?

Official patient information notes that teeth discoloration has been reported. This occurred when the product was broken or held in the mouth prior to swallowing. Official guidance is that to prevent this, the tablets should not be broken or held in the mouth prior to swallowing.

Q: Does Pyridium (PFIZER) interact with alcohol or specific foods?

The administration guidelines advise taking the medicine with or following food to minimize potential gastrointestinal discomfort. The official drug interaction documentation for the single-agent phenazopyridine is silent on interactions with alcohol.

Q: Are there any known drug-drug interactions with Pyridium (PFIZER)?

Official labeling generally focuses on a few key areas of interaction. This includes the potential for additive toxicological effects (such as increasing the risk of methemoglobinemia) and procedural limits on the duration of use when administered alongside an antibacterial agent.

Q: Are there any reported nervous system side effects beyond headache with Pyridium (PFIZER)?

Nervous system side effects are documented in official reports, especially those associated with drug accumulation or overdosage. These reported effects may include confusion and dizziness.

Q: Can Pyridium (PFIZER) affect the color of other body fluids, like tears or sweat?

Yes. Regulatory documents state that phenazopyridine is a dye that concentrates in the body and may cause discoloration of various body fluids, in addition to urine. Staining of contact lenses has also been reported.

How should Pyridium (PFIZER) be stored and disposed of?

Storage Requirements

Pyridium (phenazopyridine hydrochloride) must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The medication must be kept in its original container and the container must be tightly closed. Storage conditions require protection from light, excess heat, and moisture; the product must not be frozen. To ensure child safety, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused phenazopyridine should be disposed of through a medicine take-back program. If a program is unavailable, official guidelines recommend mixing the medicine with an unappealing substance, placing the mixture in a sealed bag, and discarding it in the trash. It is explicitly stated that Pyridium should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pyridium (PFIZER) found in:

A-Z Index: